Table 1. Clinical trials identified at Clinicaltrials.gov related to drug intervention for COVID-19 treatment.
| Study | Study Start | Interventions | Severity | Target Number | Phase | Status | Country |
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) | 28-Mar-20 | hydroxychloroquine +/- azithromycin | Severe/Critical | 440 | III | Recruiting | Brazil |
| Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI | 27-Mar-20 | sarilumab vs. control | Severe/Critical | 240 | II/III | Recruiting | France |
| Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC) | 24-Mar-20 | sargramostim vs. control | Severe | 80 | IV | Recruiting | Belgium, Italy |
| Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 | 23-Mar-20 | chloroquine diphosphate (high dose vs. low dose) | Severe/Critical | 440 | II | Recruiting | Brazil |
| Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome | 23-Mar-20 | methylprednisolone | Severe/Critical | 104 | II/III | Recruiting | Italy |
| Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 23-Mar-20 | colchicine vs. control | Mild | 6,000 | III | Recruiting | Canada |
| Trial of Treatments for COVID-19 in Hospitalized Adults | 22-Mar-20 | remdesivir vs. lopinavir/ritonavir +/- interferon β-1A vs. hydroxychloroquine vs. control | Severe/Critical | 3,100 | III | Recruiting | France |
| Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 | 21-Mar-20 | nitric oxide gas vs. control | Mild | 240 | II | Recruiting | United States |
| Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 | 21-Mar-20 | nitric oxide gas vs. control | Severe/Critical | 200 | II | Recruiting | United States |
| Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) | 19-Mar-20 | tocilizumab | Critical | 330 | II | Recruiting | Italy |
| Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial | 18-Mar-20 | lopinavir/ritonavir vs. control | Severe/Critical | 440 | II | Active not recruiting | Canada |
| Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 | 17-Mar-20 | hydroxychloroquine vs. control | Mild | 3,000 | III | Recruiting | United States |
| Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 16-Mar-20 | sarilumab vs. control | Severe/Critical | 400 | II/III | Recruiting | United states |
| Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. | 16-Mar-20 | baricitinib vs. control | Mild | 60 | III | Recruiting | Italy |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS- 5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 15-Mar-20 | remdesivir vs. control | Mild | 600 | III | Recruiting | Multinational* |
| Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) | 11-Mar-20 | lopinavir/ritonavir vs. hydroxychloroquine sulfate vs. control | Mild | 150 | II | Recruiting | Korea |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS- 5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 6-Mar-20 | remdesivir vs. control | Severe | 400 | III | Recruiting | Multinational† |
| Tetrandrine Tablets Used in the Treatment of COVID-19 | 5-Mar-20 | tetrandrine vs. control | Mild/Severe | 60 | IV | Enrolling by invitation | China |
| Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19 | 27-Feb-20 | YinHu QingWen Decoction vs. Chinese medicine treatment vs. standard western medicine treatment | Mild | 300 | II/III | Active not recruiting | China |
| Fingolimod in COVID-19 | 22-Feb-20 | fingolimod vs. control | Mild/Severe | 30 | II | Recruiting | China |
| Adaptive COVID-19 Treatment Trial (ACTT) | 21-Feb-20 | remdesivir vs. control | Severe/Critical | 440 | III | Recruiting | Multinational‡ |
| Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection | 17-Feb-20 | danoprevir + ritonavir +/- interferon nebulization | Mild | 11 | IV | Completed | China |
| Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu | 15-Feb-20 | N-acetylcysteine +/- Fuzheng Huayu Tablet | Mild/Severe | 136 | II | Recruiting | China |
| Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia | 14-Feb-20 | vitamine C vs. control | Severe/Critical | 140 | II | Recruiting | China |
| Mild/Moderate 2019-nCoV Remdesivir RCT | 12-Feb-20 | remdesivir vs. control | Mild | 308 | III | Recruiting | China |
| Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | 10-Feb-20 | lopinavir/ritonavir + ribavirin + lnterferon β-1B vs. control | Mild/Severe/ Critical | 70 | II | Recruiting | Hong Kong |
| A Pilot Study of Sildenafil in COVID-19 | 9-Feb-20 | sildenafil citrate | Mild/Severe | 10 | III | Recruiting | China |
| Severe 2019-nCoV Remdesivir RCT | 6-Feb-20 | remdesivir vs. control | Severe | 453 | III | Recruiting | China |
| Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV) | 6-Feb-20 | hydroxychloroquine vs. control | Mild/Severe/ Critical | 30 | III | Completed | China |
| Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia | 3-Feb-20 | meplazumab | Mild/Severe | 20 | I/II | Recruiting | China |
| Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia | Feb-20 | bevacizumab | Severe/Critical | 20 | II/III | Recruiting | China |
| A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia | 1-Feb-20 | ASC09F + oseltamivir vs. ritonavir + oseltamivir vs. oseltamivir | Mild | 60 | III | Recruiting | China |
| A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia | 1-Feb-20 | arbidol hydrochloride vs. oseltamivir vs. lopinavir/ritonavir vs. control | Mild/Severe/ Critical | 400 | IV | Recruiting | China |
| A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia | 1-Feb-20 | arbidol hydrochloride +/- lnterferon atomization | Mild/Severe/ Critical | 100 | IV | Recruiting | China |
| The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia | 1-Feb-20 | methylprednisolone (< 40 mg/day vs. 40-80 mg/day) | Severe | 100 | IV | Recruiting | China |
| Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV | 30-Jan-20 | darunavir + cobicistat vs. control | Mild/Severe/ Critical | 30 | III | Recruiting | China |
| Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure | 26-Jan-20 | methylprednisolone vs. control | Severe/Critical | 80 | II/III | Recruiting | China |
| STOP PIV - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects | 23-May-19 | DAS181 | Severe | 250 | III | Recruiting | United States |
| Lessening Organ Dysfunction With Vitamin C | 8-Nov-18 | vitamin C vs. control | Critical | 800 | III | Recruiting | Canada |
| Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections | 24-Oct-17 | nitric oxide gas | Mild | 20 | II | Active not recruiting | Canada |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | 11-Apr-16 | lopinavir/ritonavir +/- hydroxychloroquine vs. lnterferon β-1A vs. Anakinra vs. control | Severe/Critical | 6,800 | IV | Recruiting | Multinational§ |
*United States, China, Germany, Hong Kong, Italy, Korea, Singapore, Spain, Switzerland, Taiwan, United Kingdom, †United States, Germany, Hong Kong, Italy, Korea, Singapore, Spain, Switzerland, Taiwan, United Kingdom, ‡United States, Japan, Korea, Singapore.
§Australia, Belgium, Canada, Croatia, Germany, Hungary, Ireland, Netherlands, New Zealand, Portugal, Romania, Spain, United Kingdom